Low-Dose Cannabinoid Supplement Improved Sleep Quality in a Small Crossover Trial ↗
Small crossover trial found a low-dose cannabinoid supplement (3 mg THC, 6 mg CBN, 10 mg CBD) improved sleep quality and insomnia symptoms vs placebo over 10 days.
Browse more cannabis research, findings, methods, and limitations.
Small crossover trial found a low-dose cannabinoid supplement (3 mg THC, 6 mg CBN, 10 mg CBD) improved sleep quality and insomnia symptoms vs placebo over 10 days.
Pilot study of 18 CHS patients found high pain severity, elevated anxiety, extensive prior imaging workups, and a 17% 30-day ER return rate.
Among 23,900 Swedish workplace drug tests, 4.6% were positive—with cannabis the most common substance at over 40% of positive results.
Survey of 367 college students found monthly simultaneous cannabis and alcohol use predicted depression in both sexes, with possible male-specific links to anxiety and stress.
Survey of 15,208 California adults found 37% used cannabis, with 38% of users consuming multiple times daily, primarily from licensed dispensaries.
Systematic review found depression and cannabis use share brain reward processing regions but no consistent biomarkers, with cannabis amotivation vastly understudied (only 2 studies).
Researchers created CBD-like molecules from spearmint compounds that showed stronger anti-seizure effects than natural CBD in mouse models of epilepsy.
Secret shopper study of 35 Bay Area dispensaries found budtenders consistently recommended topicals for pain and edibles for sleep, based on personal experience.
German survey data across five waves (2012-2024) shows cannabis use rose steadily from 4.6% to 9.8%, with the post-legalization increase small and not statistically significant.
Survey of 239 German physicians found most expected more cannabis use after legalization, but few screened patients for it or wanted training.
Rat study found THC+CBD use caused stress responses to generalize to neutral stimuli via astrocyte changes in the nucleus accumbens, but only in males.
Five-year study of 106 cannabis poisoning cases found children more often had impaired consciousness, while adults had faster heart rates and lower oxygen. Delayed treatment worsened outcomes in children.
Off-label CBD treatment across 108 patients with various refractory epilepsies achieved 38.9% responder rate at three months, with tolerability similar to approved indications.
Analysis of 6,210 traffic-stop blood samples in Munich found cannabis was the top substance detected (66-67%) throughout the pandemic, with THC metabolite levels rising during lockdowns.
Daily diary study of 116 young adults found simultaneous alcohol and cannabis use (overlapping effects) was linked to roughly double the alcohol-related consequences compared to same-day use without overlap.
Systematic review of 63 CHS cases found capsaicin cream, antipsychotics, and benzodiazepines more effective than standard anti-nausea medications, leading to a proposed treatment algorithm.
After medical marijuana dispensaries opened, cancer surgery patients were less likely to receive strong opioid prescriptions—but just passing the law wasn't enough.
Anonymous survey found chronic pain sufferers using CBD isolate reported decreased pain at low doses with minimal side effects, though the design limits conclusions.
Mouse study found CBD reduced stress-induced liver damage by activating CB2 receptors and protective antioxidant pathways, improving inflammation, fibrosis, and mitochondrial health.
Case report of a pregnant woman with CHS unresponsive to standard anti-emetics who improved significantly with topical capsaicin cream.
Large study of 59,529 minority young adults found racial trauma undermined the mental health benefits of psychological well-being, with distinct patterns for multi-ethnic versus mono-ethnic individuals.
Interviews with 15 birthing parents found racial bias in newborn drug testing practices, poor communication about cannabis risks in pregnancy, and calls for non-punitive approaches.
Matched cohort study found patients with cannabis-related disorders received more opioid prescriptions and had more ER visits after carpal tunnel surgery, with lower outpatient follow-up rates.
PNAS study found cannabis vapor increased food intake in humans and rats by boosting eating motivation and overriding food reward signals, without altering hunger hormones.
Survey of 2,000+ Louisiana medical marijuana patients found average pain reduction of 3.4 points and evidence that MM substitutes for prescription painkillers.
Survey of 1,030 German cannabis patients found flower users consumed an average of 336 mg THC daily, nearly 20x more than those using other preparations, with implications for driving safety.
Crossover trial found CBD normalized glutathione, glutamate, and GABA levels in AUD participants who drank the day before, but had no effect in those who abstained.
Crossover fMRI trial found 800 mg CBD reduced precuneus activation during alcohol cue exposure in AUD participants, though craving and mood were unaffected.
Focus groups with 28 Washington teens found cannabis edible packaging appealing despite regulations, with cannabis-knowledgeable teens showing more skepticism.
Preclinical study found cannabichromene killed pancreatic cancer cells through multiple death pathways (apoptosis and ferroptosis) via TRPV1 and CB2 receptors, with tumor inhibition confirmed in mice.
JAMA study of 55,406 adults over 5 years found cannabis legalization increased cannabis and e-cigarette use but did not affect cigarette smoking, with cannabis use rising more after retail outlets opened.
Mouse study found CBD-rich cannabis extract was more effective than pure synthetic CBD against brain inflammation, reducing anxiety, cognitive deficits, and oxidative stress.
Meta-analysis of 6 studies with 15,000+ participants found marijuana use associated with 34% lower oral cancer risk, though authors caution about methodological limitations.
Study found THC from hemp-fed dairy cows transfers to milk above safe levels, but a 12-day withdrawal period eliminates the risk for consumers.
A 26-year-old chronic cannabis user with no heart disease had a cardiac arrest with ventricular fibrillation and QTc prolongation, requiring prolonged rehabilitation for brain injury.
Crossover RCT found 60 mg/day CBD for 7 days blunted exercise-induced liver enzyme elevations in athletes without hepatotoxicity, with medium-to-large effect sizes.
Teen cannabis use has held steady despite legalization, but ER visits, child ingestions, and product potency have all increased—changing the risk landscape.
Survey of 918 hand surgery patients found 15% had tried CBD, with only 39% of users reporting pain relief. CBD users had higher pain scores and worse function.
National ER data showed suspected CHS visits among youth (15-24) topped 55,000 from 2006-2020, with an average annual increase of 28.1%.
Zebrafish epilepsy model found cannabis extracts matched pure CBD for seizure reduction despite containing much less CBD, supporting an entourage effect.
Study of 536 teen tobacco/cannabis users found alcohol use and secondhand smoke exposure were the strongest predictors of same-day poly-product use patterns.
Study of 2,207 young adults found different types of adverse childhood experiences predicted different substance use patterns depending on racial/ethnic background.
Large study of 92,757 college students found OCD conditions independently associated with higher tobacco, cannabis, and alcohol use risk, plus more than doubled disordered eating risk.
Study of 3,823 high schoolers found same-day nicotine-cannabis use was associated with 4.28x higher odds of cannabis dependence symptoms versus using both but on different days.
Study of 1,335 psychiatric inpatients found low conscientiousness, low agreeableness, and high openness to experience associated with cannabis use disorder.
Mouse study found synthetic cannabinoids combined with fentanyl worsened respiratory depression and made naloxone rescue less effective, explaining some naloxone-resistant overdoses.
Aged obese rats given CBD showed reduced anxiety, lower circulating endotoxin, and decreased brain inflammation markers, with disrupted endocannabinoid signaling partially restored.
Difference-in-differences analysis found states with cannabis dispensaries and legal recreational cannabis had 14-20% more asthma hospitalizations than comparison states.
JAMA Psychiatry study of 110 million insured adults found medical cannabis laws associated with 31 more CUD diagnoses per 100,000 per quarter, with recreational laws linked to more cannabis poisoning.
Rat study found oral THC provided dose-dependent inflammatory pain relief (stronger in females), but adding CBD diminished THC's analgesic effects rather than enhancing them.